[{"id":"2770c644-c8c6-4b54-8f58-0b1d8f8f4795","acronym":"IO-202-CL-001","url":"https://clinicaltrials.gov/study/NCT04372433","created_at":"2023-05-17T22:04:43.287Z","updated_at":"2025-02-25T14:40:35.488Z","phase":"Phase 1","brief_title":"IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML","source_id_and_acronym":"NCT04372433 - IO-202-CL-001","lead_sponsor":"Immune-Onc Therapeutics","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • IO-202"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-14"},{"id":"4fa2d9d4-6a40-43ec-bdcf-d1701a41dac8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05309187","created_at":"2024-06-08T04:16:43.361Z","updated_at":"2024-07-02T16:34:58.981Z","phase":"Phase 1","brief_title":"Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors","source_id_and_acronym":"NCT05309187","lead_sponsor":"Immune-Onc Therapeutics","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IO-202"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2024-06-04"}]